Alessandro Vitale, Michael Volk, Umberto Cillo – 31 January 2015

Pietro Lampertico – 30 January 2015

Scott L. Friedman – 30 January 2015

Mi Na Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Ki Jun Song, Young Nyun Park, Kwang‐Hyub Han – 30 January 2015 – Early detection of liver cirrhosis in its subclinical stage is of paramount importance to identify high‐risk individuals for developing hepatocellular carcinoma (HCC). This study investigated whether transient elastography (TE) can identify patients with subclinical cirrhosis (SCC) who are at increased risk of developing HCC among chronic hepatitis B (CHB) patients without clinical evidence of cirrhosis.

Stefan M. Brunner, Christoph Rubner, Rebecca Kesselring, Maria Martin, Eva Griesshammer, Petra Ruemmele, Thomas Stempfl, Andreas Teufel, Hans J. Schlitt, Stefan Fichtner‐Feigl – 30 January 2015 – Interleukin‐33 (IL‐33), a cytokine with pleiotropic functions, is elevated in serum of patients with hepatocellular carcinoma (HCC). This study investigated the effects of local IL‐33 expression in resected HCC on patient survival and on the immunological and molecular tumor microenvironment.

Hyeon Seok Hwang, Cheol Whee Park, Myeong Jun Song – 30 January 2015 – Tenofovir disoproxil fumarate (TDF) is widely used as an effective first‐line therapy for chronic hepatitis B (CHB) infection. While TDF demonstrates successful viral suppression, it has been linked to the development of renal proximal tubular (PT) dysfunction, leading to Fanconi syndrome. However, Fanconi syndrome has been rarely reported in CHB‐monoinfected patients, and there were no reports of TDF‐associated nephrotic syndrome.

Hyeon Seok Hwang, Cheol Whee Park, Myeong Jun Song – 30 January 2015 – Tenofovir disoproxil fumarate (TDF) is widely used as an effective first‐line therapy for chronic hepatitis B (CHB) infection. While TDF demonstrates successful viral suppression, it has been linked to the development of renal proximal tubular (PT) dysfunction, leading to Fanconi syndrome. However, Fanconi syndrome has been rarely reported in CHB‐monoinfected patients, and there were no reports of TDF‐associated nephrotic syndrome.

Jeong Won Jang, Jong Young Choi, Young Seok Kim, Hyun Young Woo, Sung Kyu Choi, Chang Hyeong Lee, Tae Yeob Kim, Joo Hyun Sohn, Won Young Tak, Kwang‐Hyub Han – 27 January 2015 – The effect of viral suppression on long‐term disease outcome after decompensation in patients with hepatitis B virus (HBV)‐related cirrhosis has not been established. The aim of this study was to determine the long‐term effect of antiviral therapy (AVT) in patients with HBV‐related decompensated cirrhosis.

Yongyin Li, Weibin Wang, Libo Tang, Xuanqiu He, Xin Yan, Xiaoyong Zhang, Youfu Zhu, Jian Sun, Yongquan Shi, Xiong Ma, Ian R. Mackay, M. Eric Gershwin, Ying Han, Jinlin Hou – 27 January 2015 – The serological hallmark of primary biliary cirrhosis (PBC) is the presence of high titer and specific antimitochondrial antibodies (AMAs). Although there is no global immune defect in patients with PBC, there is widespread dysregulated B‐cell function, including increased sera levels of immunoglobulin M and enhanced B‐cell responses to cytosine‐phosphate‐guanine stimulation.

Zobair M. Younossi, Maria Stepanova, Patrick Marcellin, Nezam Afdhal, Kris V. Kowdley, Stefan Zeuzem, Sharon L. Hunt – 27 January 2015 – Treatment with interferon (IFN) and ribavirin (RBV) significantly impairs quality of life and other patient‐reported outcomes (PROs). Patient experience with IFN‐ and RBV‐free anti‐HCV (hepatitis C virus) regimens has not been reported. We assessed PROs in patients treated with ledipasvir and sofosbuvir (LDV/SOF) with and without RBV.